Using targeted mutation methods, a break in the DNA strand is induced at a specific site and subsequently is repaired by the cell's own DNA repair system. When DNA mismatches occur, the appropriate gene in no longer functional. © 123rf.com/Andrii Panchyk

EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.

Seattle headquarters of Just Biotherapeutics. ©Just Biotherapeutics, Inc
Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.

The codon-specific elongation model (COSEM) simulates protein synthesis. © Scientific Reports

Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.

© DNA Script

In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.

SBD 2019 Plenary Session. Picture: Deirdre O'Keeffe

Although the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring theme at the event in Basel was the plea for change. 

© 123rf.com/lassedesignen

Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.

EIB Vice-President Alexander Stubb and Tuomas Tenkanen, CEO of Mobidiag. © EIB

Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.

© 123rf.com/Kateryna Kon

Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two  wholly owned Phase III products. 

Amtibiotics-resistant Pseudomonas bacterium. © CDC/ James Archer

Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).

The Head of the German Ethics Council, Peter Dabrock (right), the spokesman of the group that prepared the report, Alena Buyx (second from the left) and its debuty spokesman, Andreas Lob-Hüdepohl hand out the Council's report to Anja Karliczek, the German Minister fo Research and Education. © German Ethics Council

Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.